Monograph
C01CA24 - Epinephrine |
Not porphyrinogenic |
NP |
Rationale
Endogenous catecholamine. Non-CYP dependent metabolism. No data pointing to CYP-interaction.
Chemical description
Endogenous catecholamine.
Therapeutic characteristics
Catecholamine used in asthma bronchiale, cardiac arrest, hypersensitivity reactions. Parenterally administered in 0.3-1 mg dose.
Metabolism and pharmacokinetics
Epinephrine (adrenalin) is an endogenous compound. It is very rapidly inactivated by processes which include uptake into adrenergic neurones, diffusion, and enzymatic degradation in the liver and body tissues. Metabolism involves monoamine oxidase (MAO) and catechol-O-methyl transferase (COMT).
IPNet drug reports
Uneventful use reported in 1 patient with acute porphyria.
References
| # |
Citation details |
PMID |
|---|
| * | Scientific articles |
| 1. |
MFM James, RJ Hift. Porphyrias. Br J Anaesth 2000; 85, 143-53.
|
|
| * | Drug reference publications |
| 2. |
Sweetman SC, editor. Martindale: The complete drug reference. Adrenaline. Pharmaceutical Press 2009.
|
|
Similar drugs
Tradenames and packages
From some sources, we get a list of packages (United Kingdom, Ireland, Estonia).
Other sources contain more or less "clean" versions of the trade name (Denmark, Finland, Iceland, Lithuania, Norway).
What you see here is the raw data we get from each country, so there will appear to be duplicates. The bold names
are the searchable terms. The gray names that follow are all mapped to the bolded term.
Note: The cleaning is done automatically by a proprietary algorithm, and it may produce errors.
We strive to improve it continuously.
Netherlands
Belgium
United Kingdom
Denmark
Norway
Poland
Luxembourg
Iceland
Finland
Latvia
Serbia
